. . . "* 7.7 +/- 2.7 L/h [Healthy Female Volunteers under Fasting Conditions]"@en . . "Levonorgestrel"@en . . . . . . . . "17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one"@en . . . . . . . . "investigational"@en . . . . . . "(8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy- 1,2,6,7,8,9,10,11,12,13,14,15,16, 17- tetradecahydrocyclopenta[a] phenanthren-3-one"@en . . "Levonorgestrel is not subjected to a \"first-pass\" effect and is virtually 100% bioavailable."@en . . . . . . . . . . "Levonorgestrelum"@en . "L\u00E9vonorgestrel"@en . . "d(-)-Norgestrel"@en . "LD50 >5000 mg/kg (orally in rats)"@en . . "13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one"@en . "Plan b"@en . "17alpha-Ethynyl-18-homo-19-nortestosterone"@en . "Humans and other mammals"@en . "17-alpha-Ethynyl-13-ethyl-19-nortestosterone"@en . "Take at the same time everyday."@en . "* 260 L [Healthy Female Volunteers under Fasting Conditions] * 1.8 L/kg"@en . "Binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like levonorgestrel will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge."@en . . . . "17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol"@en . . "A synthetic progestational hormone with actions similar to those of progesterone and about twice as potent as its racemic or (+-)-isomer (norgestrel). It is used for contraception, control of menstrual disorders, and treatment of endometriosis. It is usually supplied in a racemic mixture (Norgestrel, 6533-00-2). Only the levonorgestrel isomer is active. Levonorgestrel is marketed mostly as a combination oral contraceptive under several brand names such as Alesse, Triphasil, and Min-Ovral. "@en . . . . . . . . "Avoid alcohol."@en . . . . . . . . . . . . . . . . "Microluton"@en . . . . . . . "13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one"@en . . . . "Levonorgestrel"@en . "Levonova"@en . "# Edgren RA, Stanczyk FZ: Nomenclature of the gonane progestins. Contraception. 1999 Dec;60(6):313. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10715364 # Sitruk-Ware R: New progestagens for contraceptive use. Hum Reprod Update. 2006 Mar-Apr;12(2):169-78. Epub 2005 Nov 16. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16291771 # FDA label."@en . . "Avoid excessive quantities of coffee or tea (Caffeine)."@en . . . . . "approved"@en . "18-Methyl-17-alpha-ethynyl-19-nortestosterone"@en . "17-alpha-Ethinyl-13-beta-ethyl-17-beta-hydroxy-4-estren-3-one"@en . "About 45% of levonorgestrel and its metabolites are excreted in the urine and about 32% are excreted in feces, mostly as glucuronide conjugates."@en . . . . . . "17-Ethynyl-18-methyl-19-nortestosterone"@en . . " "@en . . "Take with food."@en . . . . "Mirena"@en . . "Levonelle"@en . . . "13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one"@en . . . . . . . "For the treatment of menopausal and postmenopausal disorders and alone or in combination with other hormones as an oral contraceptive."@en . . . "Increase dietary intake of magnesium, folate, vitamin B6, B12, and/or consider taking a multivitamin."@en . . . . "(-)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one"@en . "Microval"@en . "Microlut"@en . "Yu-Sheng Chang, Shu-Ping Chen, \"Levonorgestrel Crystallization.\" U.S. Patent US20090069584, issued March 12, 2009."@en . "NorLevo"@en . "55%"@en . "797-63-7"@en . . . . . . . "18-Methylnorethisterone"@en . . . . . . . . . . . . "Jadelle"@en . . . . . . . . . . . . . . . . . . . . . "Postinor"@en . . . . . . .